Oncostatin M: a Potential Biomarker to Predict Infection in Patients with Left Ventricular Assist Devices.
Oncostatin M: a Potential Biomarker to Predict Infection in Patients with Left Ventricular Assist Devices.
复制标题
DOI：
10.1097/mat.0000000000001608
复制
发表时间：
2022-08-01
期刊：
影响因子：
4.2
通讯作者：
Long, James W.
中科院分区：
文献类型：
--
作者：
Setiadi, Hendra;El-Banayosy, Ahmed M.;George, Susan;Schmidtke, David W.;El-Banayosy, Aly;Horstmanshof, Douglas A.;Long, James W.
感染是限制晚期心力衰竭患者LVAD治疗的严重不良事件，但仍然缺乏一种可靠的方法来识别感染风险增加的患者。我们假设术前血浆抑癌素M （OSM）水平升高，这是白细胞活化和炎症的细胞因子标志物，可以预测随后的感染。我们测量了41例LVAD患者在LVAD植入前一天和术后两个多月的血浆OSM。27例患者术前血浆OSM水平正常（A组，4.9±3.2 pg/mL）， 14例患者术前血浆OSM水平升高（B组，1649.0±458.9 pg/mL） （p=0.003）。两组术后早期水平均升高，A组迅速下降，B组在两个月内缓慢下降。植入后2个月内，B组感染发生率明显高于A组（p=0.004）。没有其他常规临床评估或实验室检测提供这种区分。这些发现表明，术前血浆OSM水平可能有助于识别LVAD植入后感染风险增加的患者。
Infection is a serious adverse event limiting LVAD therapy in advanced heart failure patients, but a reliable means to identify patients at increased risk of infection is still lacking. We hypothesized that pre-operative elevated levels of plasma Oncostatin M (OSM), a cytokine marker of leukocyte activation and inflammation, would be predictive of subsequent infection. We measured plasma OSM in 41 LVAD patients one day before LVAD implantation and post-operatively over two months. Pre-operative plasma OSM levels were normal in 27 patients (Group A, 4.9 ± 3.2 pg/mL) but elevated in 14 patients (Group B, 1649.0 ± 458.9 pg/mL) (p=0.003). Early post-operative levels rose in both groups and declined rapidly in Group A, with Group B declining slowly over two months. Significantly more infections developed in Group B than Group A patients over two months post-implantation (p=0.004). No other routine clinical assessment or laboratory testing afforded this differentiation. These findings suggest that pre-operative plasma OSM levels may assist in identifying patients at increased risk of infections after LVAD implantation.